News & Events

News June 29, 2026

BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder

Nearly half of individuals diagnosed with PTSD also meet criteria for major depressive disorder (MDD),...

News June 10, 2026

BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting

Preliminary Data Analysis Reveals Over 80% Remission Rate One Year after Accelerated Deep TMS Treatment,...

News May 18, 2026

BrainsWay Announces Minority-Stake Investment in Hopemark Health

Investment in provider servicing clinics in Illinois is latest in series of similar transactions by BrainsWay...

Events May 9 - May 10, 2026

LONDON, UK

LONGEVITY MED SUMMIT 2026

BrainsWay will be participating in the Longevity Med Summit 2026, taking place on May 9–10 in London,...

Events, News November 21, 2025

BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21

Deep TMS™ becomes first and only TMS device cleared in treatment of patients ages 15 to 86 suffering...

Events June 12 - June 14, 2025

Clinical TMS Society (CTMSS)

BrainsWay is attending the CTMSS conference June 13th through June 14th, in San Diego, CA. We invite...

In the media July 6, 2026

Lifestyle 5 of America’s greatest medical breakthroughs revealed as the nation marks 250 years

For most of America’s 250 years, mental illness was largely treated indirectly with medication, or...

In the media July 1, 2026

BrainsWay Featured in USA Today: America250

BrainsWay was featured in USA Today for its leadership in advancing Deep TMS™, a noninvasive treatment...

In the media November 24, 2025

FDA grants 510(k) clearance for TMS as adjunctive for major depressive disorder in young people

Key takeaways: BrainsWay Deep TMS is cleared for use by adolescents and adults with major depressive...